SCHEMBL1471275

SCHEMBL1471275

CN1C(C)(C)CC(Oc2ccc(Cl)c(C(F)(F)F)c2)CC1(C)C

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.38
EPHX2 P34913 9/20 0.37
RAF1 P04049 6/20 0.37
CCR2 P41597 2/20 0.37
HSD17B10 Q99714 1/20 0.37
BRAF P15056 2/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
CSF1R P07333 1/20 0.36
PDGFRB P09619 1/20 0.36
KIT P10721 1/20 0.36
PDGFRA P16234 1/20 0.36
FLT3 P36888 1/20 0.36
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1470312 0.99 AR (0.38) AREPHX2RAF1CCR2HSD17B10
SCHEMBL1470596 0.83 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CSF1RPDGFRB
SCHEMBL1469673 0.83 SLC6A4 (0.40) AREPHX2RAF1CCR2BRAF
SCHEMBL1473038 0.82 FPR2 (0.45) SLC6A2SLC6A4SLC6A3CSF1RPDGFRB
Hydrochloric Acid SCHEMBL1470616 0.82 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3CSF1RPDGFRB
Hydrochloric Acid SCHEMBL1471291 0.82 SLC6A4 (0.39) AREPHX2RAF1CCR2BRAF
Hydrochloric Acid SCHEMBL1471241 0.81 FPR2 (0.44) SLC6A2SLC6A4SLC6A3CSF1RPDGFRB
SCHEMBL1470859 0.80 SLC6A4 (0.39) SLC6A2SLC6A4SLC6A3CSF1RPDGFRB
Hydrochloric Acid SCHEMBL1470564 0.78 SLC6A2 (0.38) SLC6A2SLC6A4SLC6A3CSF1RPDGFRB
SCHEMBL17287081 0.77 MMP12 (0.41) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215820-A1 NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS ANIONA APS (DK) 2009-08-27 US claimed
US-7547788-B2 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2009-06-16 US claimed
US-20070167487-A1 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors ANIONA APS (DK) 2007-07-19 US claimed
EP-1761493-A2 ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-03-14 EP claimed
WO-2005123679-A2 ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2005-12-29 WO claimed
US-20110086880-A1 NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS PETERS DAN 2011-04-14 US disclosed
US-7915419-B2 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-03-29 US disclosed
US-20090215820-A1 NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS ANIONA APS (DK) 2009-08-27 US disclosed
US-7547788-B2 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2009-06-16 US disclosed
US-20070167487-A1 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors ANIONA APS (DK) 2007-07-19 US disclosed
EP-1761493-A2 ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-03-14 EP disclosed
WO-2005123679-A2 ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215820-A1 NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 AR 3315/4885EPHX2 1650/4885RAF1 3839/4885
US-20070167487-A1 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors SLC18A2, SLC6A2, SLC18A3 AR 3315/4885EPHX2 1650/4885RAF1 3839/4885
US-20110086880-A1 NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 AR 3315/4885EPHX2 1650/4885RAF1 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.